The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Current Concepts and Treatments of Schizophrenia
Open accessAbstract
Schizophrenia is a debilitating mental illness which involves three groups of symptoms, i.e., positive, negative and cognitive, and has major public health implications. According to various sources, it affects up to 1% of the population. The pathomechanism of schizophrenia is not fully understood and current antipsychotics are characterized by severe limitations. Firstly, these treatments are efficient for about half of patients only. Secondly, they ameliorate mainly positive symptoms (e.g., hallucinations and thought disorders which are the core of the disease) but negative (e.g., flat affect and social withdrawal) and cognitive (e.g., learning and attention disorders) symptoms remain untreated. Thirdly, they involve severe neurological and metabolic side effects and may lead to sexual dysfunction or agranulocytosis (clozapine). It is generally agreed that the interactions of antipsychotics with various neurotransmitter receptors are responsible for their effects to treat schizophrenia symptoms. In particular, several G protein-coupled receptors (GPCRs), mainly dopamine, serotonin and adrenaline receptors, are traditional molecular targets for antipsychotics. Comprehensive research on GPCRs resulted in the exploration of novel important signaling mechanisms of GPCRs which are crucial for drug discovery: intentionally non-selective multi-target compounds, allosteric modulators, functionally selective compounds and receptor oligomerization. In this review, we cover current hypotheses of schizophrenia, involving different neurotransmitter systems, discuss available treatments and present novel concepts in schizophrenia and its treatment, involving mainly novel mechanisms of GPCRs signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Driving fast-spiking cells induces gamma rhythm and controls sensory responses
Cardin, J. A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., & Moore, C. I. (2009) · Nature · doi:10.1038/nature08002 · Cited by 2,603
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 2×
“Moreover, aripiprazole is characterized by better t lerability comparing to other antipsychotics [134].”
BackgroundCortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Abnormal neural oscillations and synchrony in schizophrenia
Uhlhaas, P. J., & Singer, W. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2774 · Cited by 2,120
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies
Brown, A. S., & Derkits, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030361 · Cited by 1,269
Cost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wittchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,139
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
NMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Emerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498
Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars
Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S., & Minns, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703806104 · Cited by 483
Re-emergence of striatal cholinergic interneurons in movement disorders
Pisani, A., Bernardi, G., Ding, J., & Surmeier, D. J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.008 · Cited by 466
The Akt–GSK-3 signaling cascade in the actions of dopamine
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.006 · Cited by 419
Glutamate receptor expression in schizophrenic brain
Meador-Woodruff, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00044-2 · Cited by 412
Castner, S. A., Williams, G. V., & Goldman-Rakic, P. S. (2000) · Science · doi:10.1126/science.287.5460.2020 · Cited by 401
Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1141 · Cited by 372
Németh, G., Laszlovszky, I., Czobor, P., Szalai, E., Szatmári, B., Harsányi, J., Barabássy, Á., Debelle, M., Durgam, S., Bitter, I., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30060-0 · Cited by 357
History of the Discovery and Clinical Introduction of Chlorpromazine
López-Muñoz, F., Alamo, C., cuenca, E., Shen, W., Clervoy, P., & Rubio, G. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230591002002 · Cited by 354
Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., Yadav, P. N., Huang, X.-P., Feng, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104807108 · Cited by 350
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia
Takahashi, N., Sakurai, T., Davis, K. L., & Buxbaum, J. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.004 · Cited by 337
Seeger, T. F., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A., McLean, S., Guanowsky, V, Howard, H. R., & Lowe, J. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12023-5 · Cited by 322
Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803522105 · Cited by 320
Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
Dopamine D2 Receptor Dimers and Receptor-Blocking Peptides
Ng, G. Y. K., O'Dowd, B. F., Lee, S. P., Chung, H. T., Brann, M. R., Seeman, P., & George, S. R. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1489 · Cited by 273
The history of clozapine and its emergence in the US market: a review and analysis
Crilly, J. (2007) · History of Psychiatry · doi:10.1177/0957154x07070335 · Cited by 272
Laan, W., Grobbee, D. E., Selten, J.-P., Heijnen, C. J., Kahn, R. S., & Burger, H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05117yel · Cited by 264
GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
Guidotti, A., Auta, J., Davis, J. M., Dong, E., Grayson, D. R., Veldic, M., Zhang, X., & Costa, E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2212-8 · Cited by 262
Conn, P. J., Lindsley, C. W., Meiler, J., & Niswender, C. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4308 · Cited by 260
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 258
Kaiser, L. G., Schuff, N., Cashdollar, N., & Weiner, M. W. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.07.001 · Cited by 251
GABA and Schizophrenia: A Review of Basic Science and Clinical Studies
Wassef, A., Baker, J., & Kochan, L. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095349.32154.a5 · Cited by 244
Strange, P. G. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01483-2 · Cited by 240
Adenosine A2A and Dopamine D2 Heteromeric Receptor Complexes and Their Function
Fuxe, K., Ferré, S., Canals, M., Torvinen, M., Terasmaa, A., Marcellino, D., Goldberg, S. R., Staines, W., Jacobsen, K. X., Lluis, C., et al. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:26:2-3:209 · Cited by 235
The American Psychiatric Publishing textbook of psychopharmacology
(2010) · Choice Reviews Online · doi:10.5860/choice.47-4164 · Cited by 233
Ibrahim, H. M., Hogg, A. J., Healy, D. J., Haroutunian, V., Davis, K. L., & Meador-Woodruff, J. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1811 · Cited by 233
Cabungcal, J.-H., Steullet, P., Kraftsik, R., Cuenod, M., & Do, K. Q. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.020 · Cited by 232
Foster, D. J., & Conn, P. J. (2017) · Neuron · doi:10.1016/j.neuron.2017.03.016 · Cited by 226
Anti-NMDA receptor encephalitis, autoimmunity, and psychosis
Kayser, M. S., & Dalmau, J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.007 · Cited by 220
Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors
Allen, J. A., & Roth, B. L. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100553 · Cited by 216
De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., et al. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618756261 · Cited by 207
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 199
Benros, M. E., Pedersen, M. G., Rasmussen, H., Eaton, W. W., Nordentoft, M., & Mortensen, P. B. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13010086 · Cited by 192
The NMDA Receptor Hypofunction Model of Psychosis
FARBER, N. B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.008 · Cited by 190
Hirsch, L., Yang, J., Bresee, L., Jette, N., Patten, S., & Pringsheim, T. (2017) · Drug Safety · doi:10.1007/s40264-017-0543-0 · Cited by 181
Role of cannabis and endocannabinoids in the genesis of schizophrenia
Fernández‐Espejo, E., Viveros, M., Núñez, L., Ellenbroek, B. A., & de Fonseca, F. R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1612-6 · Cited by 175
Functional Imaging of Memory Retrieval in Deficit vs Nondeficit Schizophrenia
Heckers, S., Goff, D., Schacter, D. L., Savage, C. R., Fischman, A. J., Alpert, N. M., & Rauch, S. L. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1117 · Cited by 174
Grant, S., & Fitton, A. (1994) · Drugs · doi:10.2165/00003495-199448020-00009 · Cited by 173
Schizophrenia: from dopaminergic to glutamatergic interventions
Laruelle, M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.01.001 · Cited by 171
New paradigms in GPCR drug discovery
Jacobson, K. A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.085 · Cited by 169
Oxidative stress and schizophrenia: recent breakthroughs from an old story
Emiliani, F. E., Sedlak, T. W., & Sawa, A. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000054 · Cited by 169
Safety profile of iloperidone in the treatment of schizophrenia
Dargani, N. V., & Malhotra, A. K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.854770 · Cited by 167
Kusumi, I., Boku, S., & Takahashi, Y. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12242 · Cited by 166
Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 166
Arvanov, V. L., Liang, X., Schwartz, J., Grossman, S., & Wang, R. Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37013-2 · Cited by 162
Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics
Maher, A. R., & Theodore, G. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s5-b.1 · Cited by 160
A serotonin hypothesis of schizophrenia
Eggers, A. E. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.03.013 · Cited by 154
The genetics of sensory gating deficits in schizophrenia
Freedman, R., Olincy, A., Ross, R. G., Waldo, M. C., Stevens, K. E., Adler, L. E., & Leonard, S. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0032-2 · Cited by 153
Gyertyán, I., Kiss, B., Sághy, K., Laszy, J., Szabó, G., Szabados, T., Gémesi, L. I., Pásztor, G., Zájer-Balázs, M., Kapás, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.002 · Cited by 152
Partial dopamine agonists in the treatment of psychosis
Tamminga, C. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200033 · Cited by 150
Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs
Leveque, J., Macias‐Konstantopoulos, W., Rajadhyaksha, A. M., Carlson, R. R., Barczak, A. K., Kang, S., Li, X., Coyle, J. T., Huganir, R. L., Heckers, S., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04011.2000 · Cited by 148
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity
Tuplin, E. W. N., & Holahan, M. R. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170413115754 · Cited by 148
Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R. D., Stensbøl, T. B., Bundgaard, C., Arnt, J., & Kikuchi, T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213819 · Cited by 137
Citrome, L. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759211 · Cited by 134
Brunzell, D. H., & McIntosh, J. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.299 · Cited by 132
Does the dopamine hypothesis explain schizophrenia?
Lau, C. I., Wang, H.-C., Hsu, J.-L., & Liu, M. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0011 · Cited by 130
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
He, M. X., Deng, C., & Huang, X. (2013) · CNS Drugs · doi:10.1007/s40263-013-0062-1 · Cited by 129
A new mechanism of allostery in a G protein–coupled receptor dimer
Lane, J. R., Donthamsetti, P., Shonberg, J., Draper-Joyce, C. J., Dentry, S., Michino, M., Shi, L., López, L., Scammells, P. J., Capuano, B., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1593 · Cited by 124
Schizophrenia and the Motivation for Smoking
Forchuk, C., Norman, R. M. G., MALLA, A. K., Martin, M., McLean, T. S., Cheng, S. K. K., Diaz, K. M., McIntosh, E., Rickwood, A., Vos, S. H., et al. (2009) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb00656.x · Cited by 117
Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?
Madariaga‐Mazón, A., Marmolejo-Valencia, A. F., Li, Y., Toll, L., Houghten, R. A., & Martínez‐Mayorga, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.002 · Cited by 112
Clinical studies of neuroinflammatory mechanisms in schizophrenia
Watkins, C. C., & Andrews, S. R. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.018 · Cited by 111
Ghoshal, A., Rook, J. M., Dickerson, J. W., Roop, G. N., Morrison, R. D., Jalan‐Sakrikar, N., Lamsal, A., Noetzel, M. J., Poslusney, M. S., Wood, M. R., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.189 · Cited by 111
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 102
Ribeiro, E. L. A., Lima, T. D. M., Vieira, M. E. B., Storpirtis, S., & Aguiar, P. M. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2498-1 · Cited by 102
Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks
Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., & Volkmann, R. A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010005 · Cited by 99
Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia
Groß, G., Wicke, K. M., & Drescher, K. U. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0806-3 · Cited by 96
The Interaction Between GABA and Dopamine: Implications for Schizophrenia
Garbutt, J. C., & van Kammen, D. P. (1983) · Schizophrenia Bulletin · doi:10.1093/schbul/9.3.336 · Cited by 94
A Structure–Activity Analysis of Biased Agonism at the Dopamine D2 Receptor
Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, B., & Lane, J. R. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401318w · Cited by 91
Möller, H. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.5.803 · Cited by 84
How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
Kondziella, D., Brenner, E., Eyjolfsson, E. M., & Sonnewald, U. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.09.006 · Cited by 83
Godlewska, B. R., Olajossy-Hilkesberger, L., Ciwoniuk, M., Olajossy, M., Marmurowska-Michałowska, H., Limon, J., & Landowski, J. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.18 · Cited by 79
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 79
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 78
Szabó, M., Herenbrink, C. K., Christopoulos, A., Lane, J. R., & Capuano, B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500457x · Cited by 77
Smoking in schizophrenic patients: A critique of the self-medication hypothesis
Manzella, F. M., Maloney, S. E., & Taylor, G. T. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i1.35 · Cited by 75
Matosin, N., Fernandez, F., Frank, E., Deng, C., Wong, J., Huang, X., & Newell, K. A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130242 · Cited by 75
Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia
Wallace, T. L., & Bertrand, D. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.736498 · Cited by 74
Schmid, C. L., Streicher, J. M., Meltzer, H. Y., & Bohn, L. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.38 · Cited by 70
Ma, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4483-7 · Cited by 69
H1-histamine receptor affinity predicts weight gain with antidepressants
Salvi, V., Mencacci, C., & Barone‐Adesi, F. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.08.012 · Cited by 68
Gressier, F., Porcelli, S., Calati, R., & Serretti, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.035 · Cited by 64
Dunlop, J., & Brandon, N. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565806 · Cited by 63
Natesan, S., Reckless, G. E., Barlow, K. B. L., Odontiadis, J., Nóbrega, J. N., Baker, G. B., George, S. R., Mamo, D. C., & Kapur, S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1172-1 · Cited by 62
Oligomerization of G Protein-Coupled Receptors: Biochemical and Biophysical Methods
Kaczor, A. A., & Selent, J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797379285 · Cited by 62
Self-citationHashimoto, K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605111345 · Cited by 61
Jackson, J. R., Eaton, W. W., Cascella, N. G., Fasano, A., Warfel, D. T., Feldman, S. M., Richardson, C., Vyas, G. R., Linthicum, J., Santora, D., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.011 · Cited by 61
Ma, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep39209 · Cited by 61
Stott, L. A., Hall, D. A., & Holliday, N. D. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.011 · Cited by 57
The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry
Benes, F. M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.017 · Cited by 52
Allosteric Modulation of Dopamine D2 Receptors by Homocysteine
Agnati, L. F., Ferré, S., Genedani, S., Leo, G., Guidolin, D., Filaferro, M., Carriba, P., Casadó, V., Lluı́s, C., Franco, R., et al. (2006) · Journal of Proteome Research · doi:10.1021/pr0601382 · Cited by 51
Dopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum
Fuxé, K., Borroto‐Escuela, D. O., Tarakanov, A. O., Romero‐Fernandez, W., Ferraro, L., Tanganelli, S., Pérez‐Alea, M., Palma, M. D., & Agnati, L. F. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00005-2 · Cited by 50
Aringhieri, S., Kolachalam, S., Gerace, C., Carli, M., Verdesca, V., Brunacci, M. G., Rossi, C., Ippolito, C., Solini, A., Corsini, G. U., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.005 · Cited by 46
Amisulpride promotes cognitive flexibility in rats: The role of 5-HT7 receptors
Nikiforuk, A., & Popik, P. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.008 · Cited by 45
Filizola, M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.05.004 · Cited by 45
G-protein-coupled receptor type A heteromers as an emerging therapeutic target
Guidolin, D., Agnati, L. F., Marcoli, M., Borroto‐Escuela, D. O., & Fuxé, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.981155 · Cited by 45
Kim, K., & Caron, M. G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.055 · Cited by 44
Nikiforuk, A., Hołuj, M., Kos, T., & Popik, P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.035 · Cited by 43
Metabotropic Glutamate Receptors for New Treatments in Schizophrenia
Herman, E. J., Bubser, M., Conn, P. J., & Jones, C. K. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_11 · Cited by 42
Kaczor, A. A., Targowska‐Duda, K. M., Budzyńska, B., Biała, G., Silva, A., & Castro, M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.03.003 · Cited by 42
Self-citationMcRobb, F. M., Crosby, I. T., Yuriev, E., Lane, J. R., & Capuano, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201420s · Cited by 41
van Duinen, M. A., Reneerkens, O. A. H., Lambrecht, L., Sambeth, A., Rutten, B. P. F., van Os, J., Blokland, A., & Prickaerts, J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605110941 · Cited by 41
Brust, T. F., Hayes, M. P., Roman, D. L., & Watts, V. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.014 · Cited by 40
Cariprazine: New dopamine biased agonist for neuropsychiatric disorders
Deurwaerdère, P. D. (2016) · Drugs of today · doi:10.1358/dot.2016.52.2.2461868 · Cited by 40
Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 40
Brust, T. F., Hayes, M. P., Roman, D. L., Burris, K. D., & Watts, V. J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220293 · Cited by 39
Fell, M. J., Perry, K. W., Falcone, J. F., Johnson, B. G., Barth, V., Rash, K. S., Lucaites, V. L., Threlkeld, P. G., Monn, J. A., McKinzie, D. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160598 · Cited by 39
Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia
Wallace, T. L., & Bertrand, D. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.08.003 · Cited by 37
Rossi, M., Fasciani, I., Marampon, F., Maggio, R., & Scarselli, M. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107607 · Cited by 37
Weïwer, M., Xu, Q., Gale, J. P., Lewis, M., Campbell, A. J., Schroeder, F. A., de Bittner, G. C. V., Walk, M., Amaya, A., Su, P., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00168 · Cited by 34
Björkholm, C., Marcus, M. M., Konradsson‐Geuken, Å., Jardemark, K. E., & Svensson, T. H. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.01.014 · Cited by 32
Ward, S. E., Pennicott, L. E., & Beswick, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.4 · Cited by 31
Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders
Pompili, M., Verzura, C., Trovini, G., Buscajoni, A., Falcone, G., Naim, S., Nardella, A., Sorice, S., Baldessarini, R. J., & Girardi, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1379989 · Cited by 30
Improvement of ketamine-induced social withdrawal in rats
Hołuj, M., Popik, P., & Nikiforuk, A. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000132 · Cited by 27
Beyaert, M. G. R., Daya, R. P., Dyck, B. A., Johnson, R. L., & Mishra, R. K. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.010 · Cited by 27
Brexpiprazole: a new leaf on the partial dopamine agonist branch
Hope, J., Castle, D. J., & Keks, N. A. (2017) · Australasian Psychiatry · doi:10.1177/1039856217732473 · Cited by 26
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835d8296 · Cited by 23
Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs
Bartuzi, D., Kaczor, A. A., & Matosiuk, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7465-8_13 · Cited by 23
Self-citationInvestigational dopamine antagonists for the treatment of schizophrenia
Wang, S., Han, C., Lee, S.-J., Jun, T., Patkar, A. A., Masand, P. S., & Pae, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323870 · Cited by 20
Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study
Tso, I. F., Fang, Y., Phan, K. L., Welsh, R. C., & Taylor, S. F. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.022 · Cited by 19
Mombereau, C., Arnt, J., & Mørk, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.015 · Cited by 19
Comparative effectiveness of antipsychotic drugs in schizophrenia
Stroup, T. S., Lieberman, J. A., Swartz, M. S., & McEvoy, J. P. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.4/tstroup · Cited by 18
Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia
Poyurovsky, M., Bergman, J., Pashinian, A., & Weizman, A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000035 · Cited by 18
Eggers, A. E. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.08.016 · Cited by 16
Efficacy and Safety of Sertindole in Schizophrenia: A Clinical Review
Zoccali, R. A., Bruno, A., & Muscatello, M. R. A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000305 · Cited by 13
Bartuzi, D., Kaczor, A. A., & Matosiuk, D. (2017) · Molecules · doi:10.3390/molecules22071188 · Cited by 13
Self-citationSelent, J., Bauer‐Mehren, A., López, L., Loza, M. I., Sanz, F., & Pastor, M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060103 · Cited by 10
Burda, K., Kus, K., Ratajczak, P., Czubak, A., Nowakowska, E., Jędrzejewski, Ł., & Sadowski, C. (2013) · Acta Neuropsychiatrica · doi:10.1017/neu.2013.38 · Cited by 7
Prandial effect on the systemic exposure of amisulpride
Jang, Y., Jeong, T. C., Noh, K., Baek, I.-W., Kwon, K., Kim, E. Y., Yoon, Y., & Kang, W. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0331-7 · Cited by 7
Tomaka, J., Karakuła‐Juchnowicz, H., Morylowska-Topolska, J., Dzikowski, M., Juchnowicz, D., Flis, M., Siek, A., & Próchnicki, M. (2017) · Current Problems of Psychiatry · doi:10.1515/cpp-2017-0001 · Cited by 4
Cited by
Hansen, J. Y., Shafiei, G., Markello, R. D., Smart, K., Cox, S. M. L., Nørgaard, M., Beliveau, V., Wu, Y., Gallezot, J.-D., Aumont, É., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01186-3 · Cited by 797
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
Dauwan, M., Begemann, M. J. H., Slot, M. I. E., Lee, E. H. M., Scheltens, P., & Sommer, I. E. C. (2021) · Journal of Neurology · doi:10.1007/s00415-019-09493-9 · Cited by 239
Clozapine induces astrocyte-dependent FDG-PET hypometabolism
Rocha, A., Bellaver, B., Souza, D. G., Schu, G., Fontana, I. C., Venturin, G. T., Greggio, S., Fontella, F. U., Schiavenin, M. L., Machado, L. S., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05682-3 · Cited by 31
Metadata
- Authors
- Stępnicki, P., Kondej, M., & Kaczor, A. A.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2018-08-20
- Volume
- 23
- Issue
- 8
- Pages
- 2087
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2888342366
- Cited by
- 556
- References
- 161
- FWCI
- 21.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.